Cargando…
Lipid-modifying therapy in the elderly
Cardiovascular disease (CVD) mortality and morbidity increases with increasing age, largely as a result of increased lifetime exposure as well as increased prevalence of CVD risk factors. Hospitalization for CVD increases by a factor of over 18× for those aged 85+ years versus those aged <30 year...
Autores principales: | Hamilton-Craig, Ian, Colquhoun, David, Kostner, Karam, Woodhouse, Stan, d’Emden, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437602/ https://www.ncbi.nlm.nih.gov/pubmed/25999729 http://dx.doi.org/10.2147/VHRM.S40474 |
Ejemplares similares
-
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
por: Hamilton-Craig, Ian, et al.
Publicado: (2010) -
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
por: Pham, Thy, et al.
Publicado: (2016) -
Scavenger Receptor Class B Member 1 Independent Uptake of Transthyretin by Cultured Hepatocytes Is Regulated by High Density Lipoprotein
por: Landers, Kelly A., et al.
Publicado: (2019) -
Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?
por: Deed, Gary, et al.
Publicado: (2019) -
Effectiveness of the cardiac-diabetes transcare program: protocol for a randomised controlled trial
por: Wu, Chiung-Jung (Jo), et al.
Publicado: (2017)